Munich Reinsurance Co Stock Corp in Munich Takes $67.50 Million Position in Gilead Sciences, Inc. $GILD

Key Points

• Munich Re bought a new position of 608,105 Gilead shares in Q3 valued at approximately $67.5 million, representing about 1.7% of its holdings and making Gilead its 16th largest holding.
• Insiders have been net sellers: over the last three months insiders sold 309,280 shares worth about $43.9 million (including Johanna Mercier’s 28,000-share sale and CEO Daniel O'Day’s 10,000-share sale), leaving insiders with roughly 0.27% ownership.
• Gilead beat Q results (EPS $1.86 vs. $1.83 expected) with revenue of $7.93 billion, set FY2026 guidance of 8.45–8.85 EPS, and raised its quarterly dividend to $0.82 (annualized $3.28, ~2.3% yield; ex-dividend March 13).

Munich Reinsurance Co Stock Corp in Munich bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 608,105 shares of the biopharmaceutical company's stock, valued at approximately $67,500,000. Gilead Sciences comprises approximately 1.7% of Munich Reinsurance Co Stock Corp in Munich's holdings, making the stock its 16th biggest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC grew its holdings in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Ethos Financial Group LLC purchased a new position in Gilead Sciences in the 2nd quarter worth $306,000. Finally, Golden State Wealth Management LLC raised its position in Gilead Sciences by 43.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,234 shares of the biopharmaceutical company's stock worth $137,000 after purchasing an additional 371 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider owned 120,288 shares in the company, valued at $18,577,278.72. The trade was a 18.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 309,280 shares of company stock worth $43,935,470. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Down 0.7%

NASDAQ GILD opened at $144.08 on Friday. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The stock has a market capitalization of $178.86 billion, a PE ratio of 21.28, a PEG ratio of 1.90 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business's 50-day moving average is $138.29 and its 200 day moving average is $125.75.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the company posted $1.90 EPS. Gilead Sciences's quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a dividend of $0.82 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, March 13th. Gilead Sciences's dividend payout ratio is currently 46.68%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the company a "buy" rating in a research report on Wednesday, February 11th. BMO Capital Markets boosted their target price on Gilead Sciences from $135.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, January 26th. UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a "buy" rating in a report on Monday, January 26th. Truist Financial raised their price target on Gilead Sciences from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Finally, Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.